“Amnish Aggarwal is bullish on the pharma sector, noting its recent comeback driven by good numbers and attractive valuations for MNC pharma companies like GSK and Pfizer. He maintains a preference for Sun Pharma, highlighting that the sector's numbers appear sustainable due to stable raw material prices and efficiency gains.”